Compare AMTB & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | ODTX |
|---|---|---|
| Founded | 1979 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2018 | 2025 |
| Metric | AMTB | ODTX |
|---|---|---|
| Price | $30.27 | $18.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $33.25 | ★ $34.67 |
| AVG Volume (30 Days) | ★ 390.9K | 282.2K |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.81 | N/A |
| P/E Ratio | $18.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.81 | $15.10 |
| 52 Week High | $31.00 | $29.05 |
| Indicator | AMTB | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 45.36 |
| Support Level | $28.16 | $15.73 |
| Resistance Level | $30.41 | $19.60 |
| Average True Range (ATR) | 0.76 | 1.79 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 60.05 | 18.74 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.